Fate Therapeutics has announced encouraging initial data from the FT819 phase 1 autoimmunity study for people with ...

All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and ...

to Neutral from Underperform with an unchanged price target of $3 after a case study report for the first active lupus nephritis patient dosed with FT819 in the autoimmune phase 1 study ...

Fate Therapeutics (FATE) presented new clinical and translational data from the company’s FT819 Phase 1 Autoimmunity study for ...

Fate Therapeutics, Inc. (NASDAQ:FATE) recently reported positive data from its phase 1 autoimmunity study using FT819 for the treatment of patients with moderate-to-severe Systemic Lupus ...

The change comes as the company reaffirms its commitment to developing new off-the-shelf cellular immunotherapies.

FT819 is the Company’s off-the-shelf, CD19-targeted, 1XX CAR T-cell product candidate comprised of CD8αβ+ T cells with a memory phenotype and high CXCR4 expression to promote tissue trafficking.